DuPont (DD)
NYSEMaterialsChemicalsSnapshot 2026-11-04
$150.73-1.78%
Close 2026-11-04 · 1-day change
NYSEMaterialsChemicalsSnapshot 2026-11-04
Research Workspace
Put DD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Raise full year EPS to $2.35 - $2.40 in 2026: Direct metric needs a verified mapping.
View ThesisRevenue is contracting — down about 36% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 22%.
View QualityManagement screens strong on earnings delivery, the balance sheet, guidance credibility.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskDuPont's productivity gains must keep compounding to justify the price. Revenue grew 4.1% year over year in the latest quarter. The company beat its earnings estimate by 12.4%. It trades at 22 times earnings versus a 17 times peer median. The price reflects less growth than we forecast. The primary pillar is under pressure. The thesis comparison is not yet verified. Peer multiples imply a price about 6% below where it trades. The thesis is on watch.
Trailing returns as of 2026-11-04. DD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering DD (as of Nov 2026).
Based on 3 Wall Street analysts offering 12-month price targets for DD in the last 4 months.
Continue this research
Compare DD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put DD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Official transcript confirms execution against 2026 EPS and growth targets.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $150.73
The last 12 months of price, then the range of analyst 12-month targets from today’s $150.73.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Analyst confirmation of beat-and-raise supports margin and EPS objectives.
Advances: Raise full year 2026 adjusted EPS guidance to about $7.24 per share
Raised profit forecasts directly support EPS guidance objective.
Advances: Raise full year 2026 adjusted EPS guidance to about $7.24 per share
Earnings beat and raised outlook confirm growth.
Advances: Achieve slightly above 4% organic sales growth in 2026
Strong demand supports organic sales growth target.
Advances: Raise full year 2026 adjusted EPS guidance to about $7.24 per share
Raised profit forecasts align with EPS guidance.
Advances: Drive profitable growth with margin expansion and productivity
New material innovation supports profitable growth and margin expansion.
Lawsuit could impact financial performance and reputation.
